Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Open-Label Study Investigating the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma

NCT02961881 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT02961881
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02961881 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Open-Label Study Investigating the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma
Lead sponsor
Amgen
Phase
Phase 1
Overall status
Completed
Start date
September 18, 2017
Completion date
September 2, 2021
Enrollment
35 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

non-hodgkin's lymphoma